EcoDrugPlus

Glutamate Receptor Ionotropic, Nmda 2d-Like

Ensembl ID : ENSDCDG00000025679
Gene Symbol: LOC114770061
2 Cross references
215 Possible Orthologues:

Glutamate Receptor Ionotropic, Kainate 2-Like

Ensembl ID : ENSDCDG00000030630
Gene Symbol: LOC114803133
2 Cross references
252 Possible Orthologues:

Glutaminase

Ensembl ID : ENSDCDG00000026049
Gene Symbol: GLS
3 Cross references
174 Possible Orthologues:

Glutaminase Kidney Isoform, Mitochondrial-Like

Ensembl ID : ENSDCDG00000021259
Gene Symbol: LOC114790000
3 Cross references
231 Possible Orthologues:

Glycogen Synthase Kinase 3 Alpha

Ensembl ID : ENSDCDG00000023362
Gene Symbol: GSK3A
3 Cross references
175 Possible Orthologues:

Glycogen Synthase Kinase 3 Alpha

Ensembl ID : ENSDCDG00000004115
Gene Symbol: GSK3A
3 Cross references
128 Possible Orthologues:

Glycogen Synthase Kinase 3 Beta

Ensembl ID : ENSDCDG00000022805
Gene Symbol: GSK3B
3 Cross references
244 Possible Orthologues:

Gonadotropin-Releasing Hormone Ii Receptor-Like

Ensembl ID : ENSDCDG00000031947
Gene Symbol: LOC114770008
3 Cross references
174 Possible Orthologues:

Gonadotropin-Releasing Hormone Ii Receptor-Like

Ensembl ID : ENSDCDG00000028224
Gene Symbol: LOC114789914
2 Cross references
191 Possible Orthologues:

Growth Hormone Releasing Hormone Receptor

Ensembl ID : ENSDCDG00000031303
Gene Symbol: GHRHR
3 Cross references
193 Possible Orthologues:

Growth Hormone Secretagogue Receptor

Ensembl ID : ENSDCDG00000023028
Gene Symbol: GHSR
3 Cross references
196 Possible Orthologues:

Growth Hormone Secretagogue Receptor

Ensembl ID : ENSDCDG00000034779
Gene Symbol: GHSR
3 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).